key: cord-1043808-eseg0vf8
authors: Sam-Agudu, Nadia A; Rabie, Helena; Pipo, Michel Tshiasuma; Byamungu, Liliane Nsuli; Masekela, Refiloe; van der Zalm, Marieke M; Redfern, Andrew; Dramowski, Angela; Mukalay, Abdon; Gachuno, Onesmus W; Mongweli, Nancy; Kinuthia, John; Ishoso, Daniel Katuashi; Amoako, Emmanuella; Agyare, Elizabeth; Agbeno, Evans K; Jibril, Aishatu Mohammed; Abdullahi, Asara M; Amadi, Oma; Umar, Umar Mohammed; Ayele, Birhanu T; Machekano, Rhoderick N; Nyasulu, Peter S; Hermans, Michel P; Otshudiema, John Otokoye; Bongo-Pasi Nswe, Christian; Kayembe, Jean-Marie N; Mbala-Kingebeni, Placide; Muyembe-Tamfum, Jean-Jacques; Aanyu, Hellen Tukamuhebwa; Musoke, Philippa; Fowler, Mary Glenn; Sewankambo, Nelson; Suleman, Fatima; Adejumo, Prisca; Tsegaye, Aster; Mteta, Alfred; Noormahomed, Emilia V; Deckelbaum, Richard J; Zumla, Alimuddin; Mavungu Landu, Don Jethro; Tshilolo, Léon; Zigabe, Serge; Goga, Ameena; Mills, Edward J; Umar, Lawal W; Kruger, Mariana; Mofenson, Lynne M; Nachega, Jean B
title: The Critical Need for Pooled Data on COVID-19 in African Children: An AFREhealth Call for Action through Multi-Country Research Collaboration
date: 2021-02-13
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab142
sha: 76659cf8b9778bf0e33c53c2b937272f58280891
doc_id: 1043808
cord_uid: eseg0vf8

Globally, there are prevailing knowledge gaps in the epidemiology, clinical manifestations, and outcomes of SARS-CoV-2 infection among children and adolescents; however, these gaps are especially wide in African countries. The availability of robust age-disaggregated data is a critical first step in improving knowledge on disease burden and manifestations of COVID-19 among children. Furthermore, it is essential to improve understanding of SARS-CoV-2 interactions with comorbidities and co-infections such as HIV, tuberculosis, malaria, sickle cell disease and malnutrition, which are highly prevalent among children in sub-Saharan Africa. The African Forum for Research and Education in Health (AFREhealth) COVID-19 Research Collaboration on Children and Adolescents is conducting studies across Western, Central, Eastern, and Southern Africa to address existing knowledge gaps. This consortium is expected to generate key evidence to inform clinical practice and public health policymaking for COVID-19, while concurrently addressing other major diseases affecting children in African countries.

M a n u s c r i p t

There continues to be a global upsurge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and associated novel coronavirus disease . As of January 31, 2021, the World Health Organization (WHO) reported more than 102 million confirmed cases and 2.2 million deaths globally [1] . The African Region has recorded nearly 2.6 million cases and over 62,000 deaths due to COVID-19 [1] . However, there is a significant knowledge gap with respect to COVID-19 epidemiology among children. To date, available data indicates that children and adolescents 0-19 years of age (hereafter referred to as 'children') constitute a relatively small proportion of COVID-19 cases worldwide. Systematic reviews based on data largely from China, the United States (US), Spain, and other European and Asian countries report that children comprise 1 to 5% of all COVID-19 cases reported [2] [3] [4] . A recent meta-analysis of 107 datasets from 47 studies in 23 countries estimated a 3.4% SARS-CoV-2 general seroprevalence globally; prevalence in children was reported at 2.3% [5] . It is worth noting that the meta-analysis reported significantly high heterogeneity (I 2 =99.4%) for the overall estimate, and the pediatric data was based on 11 datasets, with only one dataset from an African country -Kenya [5] .

The WHO's COVID-19 global surveillance data from January through July 2020 indicated that most confirmed cases reported are in the year age group, with only 3.7% reported among children under age 15 years [6] . However, 72% of cases in this database were reported from the Americas and Europe. Evidence from primarily high-income countries with higher proportions of older populations may not be valid for the younger populations in low-and middle-income countries. The age distribution of cases partly reflects the A c c e p t e d M a n u s c r i p t population's age structure and the age-dependent probability of being tested. While data from high-income countries show that younger individuals are less likely to develop symptomatic disease than older adults, there are additional factors in Africa, such as the health effects of food insecurity and high prevalence of communicable diseases, which may counteract potential age-related protective factors for disease [7] . Of concern is that the WHO COVID-19 Situation Reports have not consistently included age-disaggregated data, and the WHO-African region has not provided such data on their public website to date.

Given the limited data available to estimate pediatric COVID-19 burden, UNICEF re-analyzed country-level data from the Max Planck Institute for Demographic Research (MPIDR) on SARS-CoV-2 infection among children under age 20 years [8] . Since not all countries routinely report COVID-19 data by standard age group and sex, the MPIDR team redistributed unknown age group measures to standardized 5-year age groups using the 2019 World Population Prospects, with reference to the year 2020. Using available agedisaggregated data from 87 countries (which account for 54% of global SARS-CoV-2 infections), they estimated that as of November 2020, children accounted for 11% of reported COVID-19 cases [8] . The proportion of confirmed positive cases in children < 20 years old varied widely between countries, ranging from 1.1% to 30%. Of these cases, 68%

were among 10-to 19-year-old patients, and 32% among the 0 to 9-year-old group. In sub-Saharan Africa (SSA), the volume and detail of available pediatric COVID-19 data remain inadequate at both country and regional level, and many knowledge gaps and research questions so far remain unanswered (Table 1, Figure 1 ).

A c c e p t e d M a n u s c r i p t

There is an expanding pool of data on the manifestations and clinical outcomes of COVID-19 among children. So far, most of this data is from China, followed by the US, Spain, the UK, and other European and Asian countries [2-4, 9, 10] . Overall, reported disease severity has been lower, and clinical outcomes (including case fatality rates) better among children, compared to adults. A recent meta-analysis by Li et al. included 96 studies involving >7,000 children with confirmed COVID-19; the mean age of children across 49 studies with agedisaggregated data was 6.48 years (95% CI 5.20-7.75) [10] . The most common presenting symptoms were fever (47%) and cough (42%), while 23% of children had no symptoms at presentation. The prevalence of severe/critical disease was 7% among children <5 years and 3% for those ≥5 years old, with an overall mortality rate of 1% [10] . Data shown here should be interpreted with caution, as the number and size of datasets used for the analyses varied across different pediatric age groups and by inclusion criteria.

There are few reports on COVID-19 in children from SSA. The largest cohort reported to date is from South Africa, comprising 159 children <13 years old with PCR-confirmed SARS-CoV-2 infection presenting to Tygerberg Hospital, Cape Town, between April and July 2020 [11] . Children in this South African cohort were relatively young (median age 48 months), but this is likely due to data collection being limited to those under age 13 years. Of the 159 children, 81 (50.9%) were symptomatic, with cough (88.9%, 72/81) and fever (61.7%, 50/81) predominating symptomatology at presentation. A total of 51 children (32.1%) required hospital admission for symptomatic care. Lower respiratory tract infection (pneumonia) was A c c e p t e d M a n u s c r i p t the most common reason for admission (41.2%), particularly for children less than 3 months old (68.8%). Multisystem Inflammatory Syndrome in Children temporally related to COVID-19 (MIS-C) was diagnosed in three children. Intensive care admission was required for 11 of 51 children admitted (21.6%), out of which four required mechanical ventilation. Median length of hospital stay was five days, and despite severity, there were no deaths among children admitted in intensive care; there was one death in a five-week-old HIV-exposed, uninfected infant, which was determined secondary to sepsis and not directly due to COVID-19.

MIS-C, also known as Pediatric Multisystem Inflammatory Syndrome temporally associated with COVID-19 (PIMS), is a newly recognized severe manifestation of SARS-CoV-2 infection that mimics Kawasaki disease and toxic shock syndrome [12] . The earliest reports of MIS-C/PIMS were from Italy in May 2020 [13] , the United Kingdom (UK) [14] and the US [15] in June 2020. MIS-C has rarely been described among the relatively large Chinese COVID-19 pediatric cohorts to date [10] ; however, this may be due to many reports predating the recognition of this syndrome. MIS-C has begun to be reported from SSA, with the largest case series to date (N=23) from South Africa; mean age was 6.6 years, 80% were Black, and all survived [16] . In a separate report, four South African children with confirmed SARS-CoV-2 infection were initially diagnosed with acute appendicitis; three had an appendectomy and were subsequently diagnosed with MIS-C, and one was managed non-surgically with no MIS-C diagnosis [17] . Besides the South African cohorts described [11, 16, 17] , the mention of MIS-C is notably absent from the few small SSA studies reporting COVID-19 manifestations and/or outcomes among children e.g. from Ethiopia [18] , Nigeria [19, 20] , A c c e p t e d M a n u s c r i p t Ghana [21] , the Democratic Republic of the Congo (DRC) [22] , and Sierra Leone [23] . This may be due to the under-recognition of MIS-C and its potential to manifest among African children. In the US and the UK, Black children have been reported to have significantly higher SARS-CoV-2 test positivity rates and higher rates of severe COVID-19/MIS-C than their non-Black counterparts [24] [25] [26] [27] . Furthermore, in a well-characterized cohort of 766 hospitalized COVID-19 patients in DRC, in-hospital mortality among 34 children <20 years old (11.4%) was unexpectedly high, and second only to that of the ≥60-year age-group (32.0%) [22] with no clear explanation. This DRC study's small pediatric sample size and the possible effects of unmeasured confounding factors, such as the quality and scope of pediatric intensive care, precluded concrete conclusions about excess COVID-19 mortality among children in this setting.

A recent systematic review of 443 studies and 145 national reports data by Kitano et al. suggests that children in low-and middle-income countries (LMICs) have poorer COVID-19 outcomes compared to those in higher-income countries [28] . They analyzed data from 3,788 global pediatric COVID-19 deaths, 91.5% of which were reported from LMICs; in fact, 83.5% of reported pediatric cases were in LMICs. COVID-19 case fatality rate was significantly higher among children in LMICs than in higher-income countries (0.24% vs 0.01%, respectively, p<0.001), while intensive care unit admissions were significantly lower, and the highest case fatality rates were among infants less than a year old. The authors additionally noted that 1) many countries failed to report age-disaggregated outcome data for children, 2) there was a lack of national-level data, particularly for children in Africa and the Middle East, and 3) there was a paucity of intensive care unit admission data from LMICs A c c e p t e d M a n u s c r i p t [28] . It would be important to evaluate pediatric (including neonatal) COVID-19 outcomes in multi-country studies across Africa to augment our understanding of the prevalence of SARS-CoV-2 infection and degree and impact of severe disease in this population (Table 1,   Figure 1 ).

Where evaluated for, acute co-infections were commonly identified among children with COVID-19; a 29% co-infection rate was determined in the systematic review by Li et al. [10] .

Mycoplasma spp, followed by influenza A, influenza B, Epstein-Barr virus, adenovirus, and respiratory syncytial virus were most predominant microorganisms [10] . In a South African cohort (N=159), two (1.3%) children were HIV-infected and 13 (8.2%) were HIV-exposed but uninfected; other pre-existing conditions included sickle cell disease (SCD), aplastic anemia, asthma, prematurity, and tuberculosis [11] . Of note, seven children had a recent or current diagnosis of tuberculosis; two children were on anti-tuberculosis treatment at presentation, and an additional four children received a new tuberculosis diagnosis during admission [11] .

Infectious diseases such as HIV, tuberculosis, malaria and non-communicable diseases such as SCD and malnutrition are highly prevalent among children in SSA, and can pose significant diagnosis and disease management challenges at individual and public health level if coexisting with COVID-19 [29] . A meta-analysis by Tsankov et al. determined that children with underlying co-morbidities, such as chronic respiratory disorders (including asthma), immune disorders (including 'immunosuppression' but not HIV), cardiovascular disease, metabolic disorders (including diabetes), obesity, neurologic disorders, hematologic disorders (including SCD), and cancers have significantly more severe COVID-19 manifestations and higher associated mortality [30] . More studies are needed to determine A c c e p t e d M a n u s c r i p t the impact of co-morbidities common in the SSA region on pediatric COVID-19 outcomes [29] (Table 1, Figure 1 ).

In the wake of the COVID-19 pandemic, several countries and regions have established research consortia to generate evidence for policy and practice on prevention and treatment, including among children. The pediatric consortia have leveraged pre-existing networks, e.g., the Pediatric Tuberculosis Network European Trials Group (ptbnet) [31] , or have forged new alliances, e.g., the CoviDOMINGO (COVID in South American Children) study group [32] . In SSA, South Africa, which has by far the highest number of COVID-19 cases in Africa, has established the Cape Town MIS-C Team [16] which is part of an ongoing drive to expand in-country MIS-C collaboration. Additionally, the South African COVID-19 in Children Research Network is coordinated by the South African Medical Research Council [33] . Within-country collaborations are needed to generate local evidence to shape national responses for children, while multi-country and intra-regional collaborations will make it possible and easier to rigorously address additional research questions, particularly those with rare outcomes. Pooling data across countries has the advantages of enhancing statistical power and the ability to compare outcomes across sites or settings (increased internal validity), as well as generalizability of the findings to the continent (increased external validity). The African Forum for Research and Education in Health (AFREhealth) [34] has assembled a multi-country team of pediatric and infectious disease clinicians and researchers to address the paucity of pediatric COVID-19 evidence in Africa, starting with SSA. Furthermore, AFREhealth has established a multi-country COVID-19 Research

Collaboration group that has prioritized pregnant women and neonates for studies spanning A c c e p t e d M a n u s c r i p t Western, Central, Eastern, and Southern Africa [35] . These consortia will serve as a ready resource for further prospective and retrospective COVID-19 studies to drive the response at country, regional and/or continental level.

Adolescents was necessary was the relative lack of public health data on pediatric COVID-19 at the SSA country and regional level. Health information systems (HIS) are an essential building block of health systems and allow for rapid review of data for evidence-based decision-making and efficient use of resources. HIS challenges in SSA were well-described prior to the COVID-19 pandemic; an overreliance on household surveys and poor integration of other, key data sources (e.g., civil registration and health facility statistics, especially from the private sector) were noted [36] . To date, measures to strengthen HIS in SSA include the African Health Initiative's Population Health Implementation and Training Partnership, established in 2010 [37] . It focused on strengthening district health systems and improving health planning in five SSA countries. Currently, it is unclear whether and how the partnership is contributing to COVID-19 reporting and decision-making in the respective countries. The importance of national public health agencies and prior experience with outbreaks such as Ebola has been reported, in addition to how ineffective governance and chronically poor HIS have affected prior outbreaks and ongoing COVID-19 responses [38, 39] .

Private facility data are often not included in national reports, and few countries have highly functioning HIS with transparent data-sharing for COVID-19. Unique issues for children include outright exclusion or poorly age-disaggregated data, both in public health and in A c c e p t e d M a n u s c r i p t research reports. Research consortia -especially those that are child-focused -can bridge some of these gaps as follows: engaging investigators and/or including data from private clinics and smaller district (versus larger referral) facilities to present more representative findings; incorporating verbal or social autopsy studies to provide or support mortality data that may be unavailable or inadequate; and initiating large-scale primary or secondary data collection from health facilities, especially where (pediatric) data is not being collected, reported, or age-disaggregated by public health agencies.

Critical knowledge gaps remain about the epidemiology, clinical manifestations, and outcomes of SARS-CoV-2 infection in African children. Prevailing weak HIS further complicate data collection to address these gaps. While available data may be more robust and accessible in higher-income countries outside SSA, knowledge regarding COVID-19 among children is far from adequate, even in those settings. For many reasons, including population demographics, health system infrastructure, potentially genetics and other disease epidemiology, it is difficult to draw comparisons between pediatric COVID-19 data from SSA and those from other geographic regions. It remains, however, that more data are needed from all over the world. Initiatives such as AFREhealth's child-focused, multi-country research consortium and emerging in-country collaborations (e.g., the South African [29]  What is the impact of SCD on risk and outcomes of COVID-19 disease among children in SSA? [29]  How do cardiovascular, metabolic, and other comorbidities impact the risk and outcomes of COVID-19 in African children?  How do housing density, crowding and household air pollution affect risk of SARS-CoV-2 infection in children in SSA?  What is the prevalence of depression and stigma experienced among children with COVID-19, or in the context of the COVID-19 pandemic in Africa?

Outcomes  In HIC children, disease less severe than in adults but limited SSA data suggests possible high rates of hospitalization/higher need for intensive care for younger children with COVID-19 (South Africa) [17] and possible increased mortality among adolescents (DRC) [22]  Longer-term consequences (e.g., cardiac, neurologic) post-recovery are being observed primarily among adults in HIC  How do outcomes in African children with COVID-19 disease differ from adults (and from children in HIC)?  What are the independent factors that may impact pediatric outcomes of COVID-19 in Africa?  What are the healthcare system-related vs. individual factors that may impact outcome?  What are the long-term consequences of SARS-CoV-2/COVID- 19 in African children?

6

 Intensive care/respiratory support may be less available in SSA  Limited availability of treatment drugs (e.g., remdesivir, monoclonal antibody) in SSA vs HIC  Role of BCG in COVID-19 acquisition, prevention, and severity

 What are key low cost and effective intensive care interventions that improve outcome of children with severe COVID-19 in SSA?  Is BCG vaccination potentially protective against COVID-19?  What is COVID-19 vaccine efficacy and safety in children vs. adults in Africa?  How to prioritize vaccine access for children in Africa? [29] 

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. 2020

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis

SARS-CoV-2 (COVID-19): What Do We Know About Children? A Systematic Review

SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis

World Health Organization. WHO COVID-19 Situation Report

A SARS-CoV-2 Surveillance System in Sub-Saharan Africa: Modeling Study for Persistence and Transmission to Inform Policy

Averting a lost COVID generation: A six-point plan to respond, recover and reimagine a post-pandemic world for every child

The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review

Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis

Clinical experience with SARS CoV-2 related illness in children -hospital experience in Cape Town, South Africa

Africa Centres for Disease Control and Prevention. Health Advisory: Multisystem Inflammatory Syndrome in Children and Adolescents Temporally Related to COVID-19 2020

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Multisystem Inflammatory Syndrome in Children in New York State

Multisystem inflammatory syndrome in children in South Africa

Acute Appendicitis in Multisystem Inflammatory Syndrome in Children With COVID-19

Epidemiological characteristics and treatment outcomes of hospitalized patients with COVID-19 in Ethiopia

Profile of children with COVID-19 infection: a cross sectional study from North-East Nigeria

COVID-19 in children: a case series from Nigeria

Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study

Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo

Clinical presentations and management of COVID-19 infected children seen in a district health facility in Kambia, northern Sierra Leone

African American children are at higher risk of COVID-19 infection

Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States

SARS-CoV-2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth

Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study

The differential impact of pediatric COVID-19 between high-income countries and low-and middle-income countries: A systematic review of fatality and ICU admission in children worldwide

Things must not fall apart: the ripple effects of the COVID-19 pandemic on children in sub-Saharan Africa

Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children: A Multinational Study

Research Collaboration on COVID-19 in Children

Medical Education Partnership Initiative gives birth to AFREhealth

Effect of SARS-CoV-2 Infection in Pregnancy on Maternal and Neonatal Outcomes in Africa: An AFREhealth Call for Evidence through Multicountry Research Collaboration

Health information systems in Africa: descriptive analysis of data sources, information products and health statistics

Improving health information systems for decision making across five sub-Saharan African countries: Implementation strategies from the African Health Initiative

Using critical information to strengthen pandemic preparedness: the role of national public health agencies

Optimizing Pandemic Preparedness and Response Through Health Information Systems: Lessons Learned From Ebola to COVID-19

M a n u s c r i p t the Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA), for the Central and West Africa Implementation Science Alliance (CAWISA). to COVID-19 treatments and vaccines effective for children [29] 7

 Access to SARS-CoV-2 PCR/antigen and antibody testing in SSA limited, particularly for children  Access to higher-level ancillary COVID-19 tests e.g., D-dimer, IL-6, IL-10, troponin, brain natriuretic peptide  Access to basic care (e.g., oxygen) at primary, secondary and tertiary hospital level of care; lack of intensive care and mechanical ventilation facilities  Lower quality of care contributing to excess mortality  What low cost, highly sensitive molecular antigen and antibody tests can be made available for broader testing of children in SSA?  How could access to critical ancillary tests be expanded, especially for children with MIS-C or other severe COVID-19 manifestations?  How does differential access to, and quality of healthcare impact clinical pediatric COVID-19 outcomes within (e.g., urban vs rural) and across African countries? [28]  Is there excess COVID-19 mortality among SSA children vs HIC children, and is this associated with quality of healthcare? [35] SSA A c c e p t e d M a n u s c r i p t Figure 1